The goals of the Virology Core are to enhance the research capacity of the UNC CFAR research community by providing access to state-of-the-art tools for diagnosis and monitoring HIV+ patients in clinical trials, and providing leadership to promote HIV/AIDS research in this area through collaboration, training, and mentoring.
The specific aims are to 1) provide quality viral assays and services, 2) provide training and mentorship to the domestic and international CFAR community and build capacity at international sites, 3) provide leadership through activities locally, nationally, and internationally, 4) support NIH networks and CFAR-CFAR collaborations by participating in CHAVI, HPTN, IMPAACT, and ACTG, 5) support new CFAR initiatives through collaborations with UNC CFAR members, and 6) engage in evaluation and strategic planning, using input from user surveys, an Internal Advisory Board, and the CFAR External Advisory Board. Through these activities, the Virology Core will continue to provide key infrastructure support for the HIV/AIDS research activity of the CFAR membership. These activities will have a significant impact on the future of the epidemic by providing HIV, HCV, and HPV viral assays, including ultra-low copy number and POC assays, training and mentoring new US and international scientists, and providing leadership locally, nationally, and globally.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI050410-17
Application #
8708739
Study Section
Special Emphasis Panel (ZAI1-ELB-A)
Project Start
2014-08-01
Project End
2016-07-31
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
17
Fiscal Year
2014
Total Cost
$224,485
Indirect Cost
$72,590
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Buchanan, Ashley L; Hudgens, Michael G; Cole, Stephen R et al. (2018) Generalizing Evidence from Randomized Trials using Inverse Probability of Sampling Weights. J R Stat Soc Ser A Stat Soc 181:1193-1209
Muessig, Kathryn E; Knudtson, Kelly A; Soni, Karina et al. (2018) ""I DIDN'T TELL YOU SOONER BECAUSE I DIDN'T KNOW HOW TO HANDLE IT MYSELF."" DEVELOPING A VIRTUAL REALITY PROGRAM TO SUPPORT HIV-STATUS DISCLOSURE DECISIONS. Digit Cult Educ 10:22-48
Bradley, Todd; Ferrari, Guido; Haynes, Barton F et al. (2018) Single-Cell Analysis of Quiescent HIV Infection Reveals Host Transcriptional Profiles that Regulate Proviral Latency. Cell Rep 25:107-117.e3
Adimora, Adaora A; Ramirez, Catalina; Benning, Lorie et al. (2018) Cohort Profile: The Women's Interagency HIV Study (WIHS). Int J Epidemiol 47:393-394i
Garrett, Katy L; Chen, Jingxian; Maas, Brian M et al. (2018) A Pharmacokinetic/Pharmacodynamic Model to Predict Effective HIV Prophylaxis Dosing Strategies for People Who Inject Drugs. J Pharmacol Exp Ther 367:245-251
Ong, Jason J; Wei, Chongyi; Pan, Stephen et al. (2018) Individuals have the right to avoid sex with partners unwilling to test for HIV but do not have a right to force them to test for HIV. J Acquir Immune Defic Syndr :
Qin, Yilu; Han, Larry; Babbitt, Andrew et al. (2018) Experiences using and organizing HIV self-testing. AIDS 32:371-381
Hightow-Weidman, Lisa B; Muessig, Kathryn; Rosenberg, Eli et al. (2018) University of North Carolina/Emory Center for Innovative Technology (iTech) for Addressing the HIV Epidemic Among Adolescents and Young Adults in the United States: Protocol and Rationale for Center Development. JMIR Res Protoc 7:e10365
Haas, David W; Bradford, Yuki; Verma, Anurag et al. (2018) Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics 28:179-187
Henderson, Gail E; Peay, Holly L; Kroon, Eugene et al. (2018) Ethics of treatment interruption trials in HIV cure research: addressing the conundrum of risk/benefit assessment. J Med Ethics 44:270-276

Showing the most recent 10 out of 1688 publications